Top Page
Lumos Diagnostics Holdings Ltd.
(Sydney:LDX)
Lumos Diagnostics Holdings Ltd. (LDX) vs. iShares MSCI Australia ETF (EWA)
Lumos Diagnostics Holdings Ltd. Business Overview & Revenue Model
Lumos Diagnostics Holdings Ltd. Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.67M | 11.13M | 10.54M | 11.63M | 18.85M | 5.79M |
| Gross Profit | 9.37M | 7.10M | 5.97M | 4.46M | 8.60M | 2.51M |
| EBITDA | -3.66M | -5.44M | -4.93M | -18.67M | -10.69M | -10.41M |
| Net Income | -4.98M | -8.59M | -8.97M | -45.72M | -15.03M | -9.28M |
Balance Sheet | ||||||
| Total Assets | 26.49M | 26.84M | 25.42M | 36.94M | 97.99M | 30.28M |
| Cash, Cash Equivalents and Short-Term Investments | 5.53M | 6.48M | 3.02M | 7.98M | 44.89M | 850.93K |
| Total Debt | 7.81M | 8.06M | 9.79M | 7.19M | 7.20M | 3.24M |
| Total Liabilities | 16.70M | 19.73M | 15.92M | 19.05M | 39.71M | 8.12M |
| Stockholders Equity | 9.79M | 7.11M | 9.50M | 17.89M | 58.28M | 22.16M |
Cash Flow | ||||||
| Free Cash Flow | -589.00K | 848.00K | -9.79M | -22.39M | -16.77M | -10.28M |
| Operating Cash Flow | -529.00K | 946.00K | -9.64M | -18.04M | -10.89M | -3.76M |
| Investing Cash Flow | -97.00K | -98.00K | 4.31M | -4.36M | -8.33M | -6.52M |
| Financing Cash Flow | 5.20M | 2.63M | 652.00K | -10.92M | 63.27M | 8.12M |
Lumos Diagnostics Holdings Ltd. Technical Analysis
Lumos Diagnostics Holdings Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | AU$2.47B | 4.40 | -64.25% | 2.83% | 36.51% | 13.14% | |
45 Neutral | AU$20.96M | ― | -51.49% | ― | 80.84% | 57.59% | |
45 Neutral | AU$86.31M | ― | -47.52% | ― | 44.61% | 16.40% | |
45 Neutral | AU$41.30M | ― | -39.07% | ― | 26.07% | 0.85% | |
40 Neutral | AU$24.52M | ― | -104.23% | ― | ― | -17.26% | |
39 Underperform | AU$43.26M | ― | -33.42% | ― | 158.37% | 36.73% | |
38 Underperform | AU$14.81M | ― | -71.10% | ― | ― | 76.17% |
Lumos Diagnostics Holdings Ltd. Corporate Events
Lumos Diagnostics Holdings Ltd. announced the cessation of certain securities due to unmet conditions or expiration. This development may impact the company’s capital structure and could influence investor perceptions, as it reflects on the company’s ability to meet certain financial or operational milestones.
Lumos Diagnostics has received a cash refund of A$215,485 under the Australian Government’s Research and Development Tax Incentive for its FY2024 efforts. This refund supports Lumos’ ongoing R&D in enhancing its diagnostic technology platform, which is crucial for securing partnerships and advancing point-of-care technologies.
Lumos Diagnostics has achieved a significant milestone in its FebriDx CLIA waiver clinical study by enrolling its 500th patient, triggering a milestone payment from its partner BARDA. The study aims to secure a CLIA waiver from the U.S. FDA, which would allow broader use of FebriDx in various healthcare settings, potentially unlocking a U.S. market exceeding $1 billion. With the study expected to conclude by Q4 2025, Lumos plans to submit its CLIA waiver application in October 2025, which could enhance point-of-care decision-making and antibiotic stewardship in the U.S. healthcare system.
Lumos Diagnostics has announced that its FebriDx point-of-care test will be used in the University of Wollongong’s OPTIMAS-GP Trial, which aims to reduce unnecessary antibiotic prescribing for respiratory infections in primary care settings. This trial, funded by the Australian Government’s Medical Research Future Fund, will evaluate the feasibility and acceptability of FebriDx in Australian general practice, marking its first formal evaluation in this setting. The initiative is part of a broader effort to combat antimicrobial resistance by promoting evidence-based clinical decisions, and Lumos will provide approximately 2,000 test kits at a reduced cost.
Lumos Diagnostics, a leader in rapid point-of-care diagnostic technologies, has announced a change in its registered office and principal place of business to a new address in Melbourne, Australia. This move is part of the company’s ongoing efforts to streamline its operations and enhance its market presence, with all other contact details remaining unchanged.
Lumos Diagnostics has secured Medicare reimbursement coverage for its FebriDx® test from a sixth Medicare Administrative Contractor (MAC), CGS Administrators, which covers Kentucky and Ohio. This achievement means Lumos now has reimbursement coverage from six out of seven MACs, representing over 85% of US Medicare payment coverage, significantly expanding its access to the Medicare patient population. This development is a critical milestone for Lumos, as Medicare often sets a precedent for private insurance payors, and it demonstrates the company’s commitment to achieving nationwide access and broad clinical adoption of FebriDx.
Lumos Diagnostics has secured Medicare reimbursement coverage for its FebriDx test from a fifth Medicare Administrative Contractor (MAC), WPS Health Solutions, retroactive from May 1, 2025. This achievement means Lumos now has coverage from five of the seven MACs, covering over 70% of US Medicare payments, which significantly enhances its access to the Medicare patient population. The company is actively negotiating with the remaining two MACs and aims to secure reimbursement from private insurers, striving for nationwide access and broad clinical adoption of FebriDx.
Lumos Diagnostics, a leader in rapid point-of-care diagnostic technologies, has announced a significant purchase order for its FebriDx test from iMedical, Inc., marking the largest single order since the test’s launch. This order underscores the growing acceptance and demand for FebriDx in the US market, following its FDA clearance in July 2023 for aiding in the diagnosis of bacterial acute respiratory infections. The collaboration with iMedical, a company known for providing cost-saving solutions to healthcare facilities, is expected to enhance the market presence of FebriDx and improve health outcomes through advanced point-of-care technology.
Lumos Diagnostics Holdings Ltd. announced the issuance of 23,000,000 unquoted performance rights as part of an employee incentive scheme. This move is aimed at enhancing employee motivation and aligning their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and market positioning positively.
Lumos Diagnostics Holdings Ltd. has released an investor briefing for Q3 FY25, emphasizing that the information is solely for informational purposes and not intended as a basis for investment decisions. The document highlights the company’s focus on providing diagnostic solutions, but it also includes disclaimers regarding the accuracy and reliability of the information, emphasizing the inherent risks and uncertainties in market data and forecasts.
Lumos Diagnostics reported a revenue of US$3.5 million for the third quarter of FY25, marking a 21% increase from the previous quarter, although down 13% from the same period last year. The company saw significant growth in its services and product revenues, with notable developments including new distribution partnerships for FebriDx® in the U.S. and the expansion of the Hologic fFN project. The company also achieved successful audit results for its quality management system, and FebriDx® was added to the Medicare Fee Schedule, potentially enhancing its market reach.
Lumos Diagnostics has secured additional U.S. Medicare reimbursement coverage for its FebriDx® test from two more Medicare Administrative Contractors (MACs), First Coast Service Options and Noridian Healthcare Solutions. This achievement expands Lumos’ Medicare coverage to four out of seven MACs, covering over 55% of U.S. Medicare payments. This milestone is crucial for the commercial success of FebriDx, as Medicare adoption often influences private insurance payors’ decisions. Lumos continues to pursue coverage from the remaining MACs and private payors to achieve nationwide access and support broad clinical adoption.
Lumos Diagnostics has achieved significant milestones in securing U.S. reimbursement for its FebriDx® test, a rapid diagnostic tool for respiratory infections. The company has obtained reimbursement coverage with two Medicare Administration Contractors, setting a reimbursement rate of $41.38 per test effective April 2025, and is progressing negotiations with additional contractors. This development is expected to facilitate broader adoption by private insurers, enhancing FebriDx’s role in improving clinical outcomes and reducing unnecessary antibiotic prescriptions.